$ORGO
Organogenesis Holdings Inc.

2023 Q2 Form 10-Q Financial Statement

#000095017023020627 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $117.3M $107.6M $98.12M
YoY Change -3.36% 9.71% -4.32%
Cost Of Revenue $26.32M $26.61M $25.08M
YoY Change -1.26% 6.09% -1.63%
Gross Profit $91.00M $81.04M $73.04M
YoY Change -3.96% 10.95% -5.22%
Gross Profit Margin 77.57% 75.28% 74.44%
Selling, General & Admin $70.32M $73.83M $63.58M
YoY Change -3.16% 16.13% 9.18%
% of Gross Profit 77.27% 91.11% 87.05%
Research & Development $10.94M $11.20M $8.587M
YoY Change 7.18% 30.45% 38.3%
% of Gross Profit 12.02% 13.82% 11.76%
Depreciation & Amortization $2.228M $2.694M $2.568M
YoY Change -18.95% 4.91% 154.26%
% of Gross Profit 2.45% 3.32% 3.52%
Operating Expenses $81.26M $85.04M $72.17M
YoY Change -1.88% 17.84% 11.99%
Operating Profit $9.745M -$4.001M $872.0K
YoY Change -18.35% -558.83% -93.09%
Interest Expense $594.0K $649.0K -$737.0K
YoY Change -181.37% -188.06% -129.84%
% of Operating Profit 6.1% -84.52%
Other Income/Expense, Net -$566.0K -$626.0K -$3.000K
YoY Change 2595.24% 20766.67% -99.88%
Pretax Income $9.179M -$4.627M $132.0K
YoY Change -17.93% -3605.3% -98.7%
Income Tax $3.863M -$1.658M $45.00K
% Of Pretax Income 42.09% 34.09%
Net Earnings $5.316M -$2.969M $87.00K
YoY Change -39.2% -3512.64% -99.13%
Net Earnings / Revenue 4.53% -2.76% 0.09%
Basic Earnings Per Share $0.04 -$0.02 -$0.01
Diluted Earnings Per Share $0.04 -$0.02 $655.10
COMMON SHARES
Basic Shares Outstanding 131.3M 131.2M 128.8M
Diluted Shares Outstanding 133.1M 131.1M 128.8M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $88.92M $88.69M $107.9M
YoY Change -20.81% -17.8% 39.22%
Cash & Equivalents $88.92M $88.69M $108.5M
Short-Term Investments
Other Short-Term Assets $8.539M $10.57M $7.740M
YoY Change 18.51% 36.54% 26.89%
Inventory $25.36M $25.54M $22.74M
Prepaid Expenses $7.948M $9.847M
Receivables $93.62M $92.02M $79.48M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $216.4M $216.8M $217.9M
YoY Change -6.52% -0.47% 17.61%
LONG-TERM ASSETS
Property, Plant & Equipment $111.8M $106.6M $131.7M
YoY Change -19.64% -19.05% 111.01%
Goodwill $28.77M $28.77M
YoY Change
Intangibles $18.33M $19.56M
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.393M $1.463M $33.46M
YoY Change -95.86% -95.63% 5161.16%
Total Long-Term Assets $233.9M $229.3M $218.4M
YoY Change 4.03% 4.97% 63.07%
TOTAL ASSETS
Total Short-Term Assets $216.4M $216.8M $217.9M
Total Long-Term Assets $233.9M $229.3M $218.4M
Total Assets $450.3M $446.1M $436.3M
YoY Change -1.32% 2.25% 36.68%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $27.39M $30.31M $27.94M
YoY Change -24.7% 8.5% 17.0%
Accrued Expenses $27.78M $28.60M $44.19M
YoY Change -42.43% -35.29% 74.11%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $5.689M $5.009M $3.227M
YoY Change 58.2% 55.22% -84.41%
Total Short-Term Liabilities $73.46M $76.08M $76.79M
YoY Change -16.75% -0.93% 3.76%
LONG-TERM LIABILITIES
Long-Term Debt $63.89M $64.86M $69.87M
YoY Change -7.36% -7.17% 10.2%
Other Long-Term Liabilities $1.190M $1.145M $46.38M
YoY Change -97.34% -97.53% 456.69%
Total Long-Term Liabilities $1.190M $1.145M $116.3M
YoY Change -98.95% -99.02% 1295.25%
TOTAL LIABILITIES
Total Short-Term Liabilities $73.46M $76.08M $76.79M
Total Long-Term Liabilities $1.190M $1.145M $116.3M
Total Liabilities $179.0M $182.4M $193.0M
YoY Change -11.36% -5.51% 19.24%
SHAREHOLDERS EQUITY
Retained Earnings -$43.57M -$48.89M -$61.75M
YoY Change -20.83% -56.15%
Common Stock $314.9M $312.6M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $271.3M $263.7M $243.2M
YoY Change
Total Liabilities & Shareholders Equity $450.3M $446.1M $436.3M
YoY Change -1.32% 2.25% 36.68%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income $5.316M -$2.969M $87.00K
YoY Change -39.2% -3512.64% -99.13%
Depreciation, Depletion And Amortization $2.228M $2.694M $2.568M
YoY Change -18.95% 4.91% 154.26%
Cash From Operating Activities $8.646M -$5.077M $1.411M
YoY Change -15.19% -459.82% -195.4%
INVESTING ACTIVITIES
Capital Expenditures $7.499M $7.562M -$6.672M
YoY Change -221.58% -213.34% -234.6%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$7.499M -$7.562M -$6.672M
YoY Change 21.58% 13.34% 39.64%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $291.0K
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -1.054M -1.236M -765.0K
YoY Change -353.98% 61.57% 29.44%
NET CHANGE
Cash From Operating Activities 8.646M -5.077M 1.411M
Cash From Investing Activities -7.499M -7.562M -6.672M
Cash From Financing Activities -1.054M -1.236M -765.0K
Net Change In Cash 93.00K -13.88M -6.026M
YoY Change -97.91% 130.25% -12.0%
FREE CASH FLOW
Cash From Operating Activities $8.646M -$5.077M $1.411M
Capital Expenditures $7.499M $7.562M -$6.672M
Free Cash Flow $1.147M -$12.64M $8.083M
YoY Change -92.99% -256.37% -225.59%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-1914000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2969000
CY2023Q1 us-gaap Preferred Stock Value
PreferredStockValue
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 us-gaap Accounting Standards Update Extensible List
AccountingStandardsUpdateExtensibleList
http://fasb.org/us-gaap/2022#AccountingStandardsUpdate201613Member
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001661181
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-37906
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
ORGANOGENESIS HOLDINGS INC.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
98-1329150
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
85 Dan Road
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Canton
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
MA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
02021
CY2023Q1 dei City Area Code
CityAreaCode
781
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
575-0775
CY2023Q1 dei Security12b Title
Security12bTitle
Class A Common Stock, $0.0001 par value
CY2023Q1 dei Trading Symbol
TradingSymbol
ORGO
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
131261833
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
88694000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
102478000
CY2023Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
721000
CY2022Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
812000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
92021000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
89450000
CY2023Q1 us-gaap Inventory Net
InventoryNet
25539000
CY2022Q4 us-gaap Inventory Net
InventoryNet
24783000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
9847000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5086000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
216822000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
222609000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106637000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102463000
CY2023Q1 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
19560000
CY2022Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
20789000
CY2023Q1 us-gaap Goodwill
Goodwill
28772000
CY2022Q4 us-gaap Goodwill
Goodwill
28772000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
42839000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
43192000
CY2023Q1 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
30014000
CY2022Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
30014000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1463000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1520000
CY2023Q1 us-gaap Assets
Assets
446107000
CY2022Q4 us-gaap Assets
Assets
449359000
CY2023Q1 us-gaap Secured Debt Current
SecuredDebtCurrent
5009000
CY2022Q4 us-gaap Secured Debt Current
SecuredDebtCurrent
4538000
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
12160000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
11708000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
30310000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
32330000
CY2023Q1 orgo Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
28597000
CY2022Q4 orgo Accrued Expenses And Other Current Liabilities
AccruedExpensesAndOtherCurrentLiabilities
26447000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
76076000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
75023000
CY2023Q1 us-gaap Secured Long Term Debt
SecuredLongTermDebt
64860000
CY2022Q4 us-gaap Secured Long Term Debt
SecuredLongTermDebt
66231000
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
40325000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
41314000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1145000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
1122000
CY2023Q1 us-gaap Liabilities
Liabilities
182406000
CY2022Q4 us-gaap Liabilities
Liabilities
183690000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
1000000
CY2023Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
400000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131954935
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
131647677
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
131226387
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
130919129
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
13000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
13000
CY2023Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
312573000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
310957000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48885000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45301000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
263701000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
265669000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
446107000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
449359000
CY2023Q1 us-gaap Revenues
Revenues
107642000
CY2022Q1 us-gaap Revenues
Revenues
97117000
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
26607000
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
25080000
CY2023Q1 us-gaap Gross Profit
GrossProfit
81035000
CY2022Q1 us-gaap Gross Profit
GrossProfit
72037000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
73834000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
63578000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11202000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
8587000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
85036000
CY2022Q1 us-gaap Operating Expenses
OperatingExpenses
72165000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4001000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-128000
CY2023Q1 us-gaap Interest Expense
InterestExpense
649000
CY2022Q1 us-gaap Interest Expense
InterestExpense
737000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
23000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-3000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-626000
CY2022Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-740000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-4627000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-868000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1658000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
45000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-2969000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-913000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.02
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.01
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.02
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.01
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
131083841
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
128788721
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
131083841
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
128788721
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
265669000
CY2023Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-298000
CY2023Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
938000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
263701000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
241335000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
-291000
CY2022Q1 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
-488000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
-1303000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-913000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
241528000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-2969000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-913000
CY2023Q1 us-gaap Depreciation
Depreciation
2694000
CY2022Q1 us-gaap Depreciation
Depreciation
1347000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1221000
CY2023Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1939000
CY2022Q1 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
1847000
CY2023Q1 orgo Non Cash Interest Expense
NonCashInterestExpense
107000
CY2022Q1 orgo Non Cash Interest Expense
NonCashInterestExpense
108000
CY2023Q1 orgo Deferred Interest Expense
DeferredInterestExpense
122000
CY2022Q1 orgo Deferred Interest Expense
DeferredInterestExpense
151000
CY2023Q1 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
243000
CY2022Q1 us-gaap Provision For Other Credit Losses
ProvisionForOtherCreditLosses
40000
CY2023Q1 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-63000
CY2023Q1 orgo Adjustment For Excess And Obsolete Inventories
AdjustmentForExcessAndObsoleteInventories
-1407000
CY2022Q1 orgo Adjustment For Excess And Obsolete Inventories
AdjustmentForExcessAndObsoleteInventories
-2205000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1914000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1303000
CY2023Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
3429000
CY2022Q1 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-2942000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2163000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-80000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
4774000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2165000
CY2023Q1 us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
2122000
CY2022Q1 us-gaap Increase Decrease In Leasing Receivables
IncreaseDecreaseInLeasingReceivables
1751000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1390000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1186000
CY2023Q1 orgo Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
2029000
CY2022Q1 orgo Increase Decrease In Accrued Liabilities And Other Current Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherCurrentLiabilities
-3828000
CY2023Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
22000
CY2022Q1 us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
10000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-5077000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
1411000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
7562000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
6672000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-7562000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6672000
CY2022Q1 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
469000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
298000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
488000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
291000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
99000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1236000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-765000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-13875000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-6026000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
103290000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
114528000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
89415000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
108502000
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
1271000
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
627000
CY2023Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
128000
CY2022Q1 us-gaap Income Taxes Paid
IncomeTaxesPaid
4000
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1986000
CY2022Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1869000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1586000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
171000
CY2023Q1 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2023Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements and the reported results of operations during the reporting periods. In preparing the consolidated financial statements, the estimates and assumptions that management consider to be significant and that present the greatest amount of uncertainty include: revenue recognition; sales returns and credit losses; inventory reserve; recognition and measurement of current and deferred income tax assets and liabilities; the assessment of recoverability of long-lived and indefinite lived assets (including intangible assets); assessing impairment of goodwill; valuation of assets and liabilities that use unobservable inputs; and the valuation and recognition of stock-based compensation. Actual results and outcomes may differ significantly from those estimates and assumptions.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p>
CY2023Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. The Company invests its cash equivalents in highly rated money market funds. Deposits may exceed federally insured limits, and the Company is exposed to credit risk on deposits in the event of default by the financial institutions to the extent account balances exceed the amount insured by the Federal Deposit Insurance Corporation (“FDIC”). However, the Company mitigates the risk by sweeping cash daily overnight and diversifies among financial institutions to reduce such exposure.</span></p>
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3782000
CY2022Q2 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0
CY2023Q1 orgo Group Purchase Organization Rebate
GroupPurchaseOrganizationRebate
1424000
CY2022Q1 orgo Group Purchase Organization Rebate
GroupPurchaseOrganizationRebate
1619000
CY2023Q1 us-gaap Revenues
Revenues
107642000
CY2022Q1 us-gaap Revenues
Revenues
97117000
CY2020Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
3782000
CY2021Q3 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
0
CY2023Q1 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
98942000
CY2022Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
95812000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6921000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
6362000
CY2023Q1 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
92021000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
89450000
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
6362000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
5153000
CY2023Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
243000
CY2022Q1 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
40000
CY2023Q1 orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-299000
CY2022Q1 orgo Allowance For Doubtful Accounts Receivable Write Offs1
AllowanceForDoubtfulAccountsReceivableWriteOffs1
-66000
CY2023Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
6921000
CY2022Q1 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
5127000
CY2023Q1 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
13126000
CY2022Q4 us-gaap Inventory Raw Materials Net Of Reserves
InventoryRawMaterialsNetOfReserves
12282000
CY2023Q1 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1158000
CY2022Q4 us-gaap Inventory Work In Process Net Of Reserves
InventoryWorkInProcessNetOfReserves
1022000
CY2023Q1 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11255000
CY2022Q4 us-gaap Inventory Finished Goods Net Of Reserves
InventoryFinishedGoodsNetOfReserves
11479000
CY2023Q1 us-gaap Inventory Net
InventoryNet
25539000
CY2022Q4 us-gaap Inventory Net
InventoryNet
24783000
CY2023Q1 orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
1407000
CY2022Q1 orgo Inventory Reserve And Obsolence Charged To Cost Of Goods Sold
InventoryReserveAndObsolenceChargedToCostOfGoodsSold
2205000
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
58523000
CY2023Q1 orgo Prepaid Subscription
PrepaidSubscription
5334000
CY2022Q4 orgo Prepaid Subscription
PrepaidSubscription
4211000
CY2023Q1 us-gaap Prepaid Advertising
PrepaidAdvertising
1277000
CY2022Q4 us-gaap Prepaid Advertising
PrepaidAdvertising
106000
CY2023Q1 orgo Prepaid Deposits
PrepaidDeposits
652000
CY2022Q4 orgo Prepaid Deposits
PrepaidDeposits
635000
CY2023Q1 us-gaap Prepaid Insurance
PrepaidInsurance
2519000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
54000
CY2023Q1 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
65000
CY2022Q4 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
80000
CY2023Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
9847000
CY2022Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
5086000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
115594000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
99697000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
65490000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
62798000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
106637000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
102463000
CY2023Q1 us-gaap Depreciation
Depreciation
2694000
CY2022Q1 us-gaap Depreciation
Depreciation
1347000
CY2023Q1 us-gaap Goodwill
Goodwill
28772000
CY2022Q4 us-gaap Goodwill
Goodwill
28772000
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
38963000
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
19560000
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
58523000
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
37734000
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
20789000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1230000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1221000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22049000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
17113000
CY2023Q1 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3041000
CY2022Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
3320000
CY2023Q1 orgo Accrued But Unpaid Lease Obligations And Interest Current
AccruedButUnpaidLeaseObligationsAndInterestCurrent
1960000
CY2022Q4 orgo Accrued But Unpaid Lease Obligations And Interest Current
AccruedButUnpaidLeaseObligationsAndInterestCurrent
2463000
CY2023Q1 us-gaap Taxes Payable Current
TaxesPayableCurrent
771000
CY2022Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
2625000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
776000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
926000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
28597000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
26447000
CY2023Q1 orgo Number Of Reduction In Employees
NumberOfReductionInEmployees
71
CY2023Q1 orgo Percentage Of Reduction In Employees
PercentageOfReductionInEmployees
0.07
CY2023Q1 us-gaap Severance Costs1
SeveranceCosts1
1817000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
1908000
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
264000
CY2023Q1 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1087000
CY2022Q4 us-gaap Restructuring Reserve Current
RestructuringReserveCurrent
1192000
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
1192000
CY2023Q1 us-gaap Restructuring Charges
RestructuringCharges
1908000
CY2023Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
2013000
CY2023Q1 us-gaap Restructuring Reserve
RestructuringReserve
1087000
CY2021Q4 us-gaap Restructuring Reserve
RestructuringReserve
3168000
CY2022Q1 us-gaap Restructuring Charges
RestructuringCharges
264000
CY2022Q1 us-gaap Payments For Restructuring
PaymentsForRestructuring
3300000
CY2022Q1 us-gaap Restructuring Reserve
RestructuringReserve
132000
CY2023Q1 us-gaap Line Of Credit
LineOfCredit
0
CY2022Q4 us-gaap Line Of Credit
LineOfCredit
0
CY2023Q1 us-gaap Secured Debt
SecuredDebt
70313000
CY2022Q4 us-gaap Secured Debt
SecuredDebt
71250000
CY2023Q1 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
444000
CY2022Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
481000
CY2023Q1 orgo Secured Debt Net
SecuredDebtNet
69869000
CY2022Q4 orgo Secured Debt Net
SecuredDebtNet
70769000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
3750000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
5625000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
6563000
CY2023Q1 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
54375000
CY2023Q1 us-gaap Long Term Debt
LongTermDebt
70313000
CY2023Q1 orgo Shares Reserved For Issuance For Outstanding Options
SharesReservedForIssuanceForOutstandingOptions
9456596
CY2022Q4 orgo Shares Reserved For Issuance For Outstanding Options
SharesReservedForIssuanceForOutstandingOptions
5931742
CY2023Q1 orgo Sharesreservedforissuanceforoutstandingrestrictedstockunits
Sharesreservedforissuanceforoutstandingrestrictedstockunits
4111720
CY2022Q4 orgo Sharesreservedforissuanceforoutstandingrestrictedstockunits
Sharesreservedforissuanceforoutstandingrestrictedstockunits
1381500
CY2023Q1 orgo Shares Reserved For Issuance For Future Grant
SharesReservedForIssuanceForFutureGrant
4831088
CY2022Q4 orgo Shares Reserved For Issuance For Future Grant
SharesReservedForIssuanceForFutureGrant
11394962
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18399404
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
18708204
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3554528
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1418224
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0399
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0192
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y2M26D
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y3M
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5100
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.5066
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
2.51
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
8.03
CY2023Q1 orgo Fair Value Of Common Share
FairValueOfCommonShare
2.47
CY2022Q1 orgo Fair Value Of Common Share
FairValueOfCommonShare
7.87
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.32
CY2022Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
3.94
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
5931042
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
5.91
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y1M20D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
2245000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
3554528
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
2.51
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
28974
CY2023Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
11.12
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
9456596
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.62
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y4M20D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
1475000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
3695292
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
4.61
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y6M29D
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1475000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
8153239
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
4.67
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y21D
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
1475000
CY2023Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
2653000
CY2022Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
1612000
CY2022Q1 us-gaap Finance Lease Right Of Use Asset Amortization
FinanceLeaseRightOfUseAssetAmortization
107000
CY2022Q1 us-gaap Finance Lease Interest Expense
FinanceLeaseInterestExpense
5000
CY2022Q1 orgo Finance Lease Cost
FinanceLeaseCost
112000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2291000
CY2022Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
2434000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
758000
CY2022Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
669000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
1794000
CY2022Q1 us-gaap Variable Lease Cost
VariableLeaseCost
918000
CY2023Q1 us-gaap Lease Cost
LeaseCost
4843000
CY2022Q1 us-gaap Lease Cost
LeaseCost
4133000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
1174000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Before Accumulated Amortization
FinanceLeaseRightOfUseAssetBeforeAccumulatedAmortization
1174000
CY2023Q1 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
1174000
CY2022Q4 us-gaap Finance Lease Right Of Use Asset Accumulated Amortization
FinanceLeaseRightOfUseAssetAccumulatedAmortization
1174000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2468000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
2337000
CY2022Q1 us-gaap Finance Lease Interest Payment On Liability
FinanceLeaseInterestPaymentOnLiability
5000
CY2022Q1 us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
99000
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
1586000
CY2022Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
171000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y3M
CY2022Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y6M14D
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0465
CY2022Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.0461
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
12157000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Rolling Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
7798000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Two
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
7678000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Three
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
7542000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due In Rolling Year Four
LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
8002000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Rolling Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
18612000
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
61789000
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
9304000
CY2023Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
52485000
CY2023Q1 orgo Accrued Legal Expenses
AccruedLegalExpenses
150000
CY2022Q4 orgo Accrued Legal Expenses
AccruedLegalExpenses
150000
CY2023Q1 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.21
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1658000
CY2023Q1 orgo Discreet Tax Expense
DiscreetTaxExpense
22000
CY2022Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
45000
CY2022Q1 orgo Discreet Tax Expense
DiscreetTaxExpense
10000

Files In Submission

Name View Source Status
0000950170-23-020627-index-headers.html Edgar Link pending
0000950170-23-020627-index.html Edgar Link pending
0000950170-23-020627.txt Edgar Link pending
0000950170-23-020627-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img118511161_0.jpg Edgar Link pending
img118511161_1.jpg Edgar Link pending
img118511161_2.jpg Edgar Link pending
img118511161_3.jpg Edgar Link pending
img118511161_4.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
orgo-20230331.htm Edgar Link pending
orgo-20230331.xsd Edgar Link pending
orgo-ex10_1.htm Edgar Link pending
orgo-ex31_1.htm Edgar Link pending
orgo-ex31_2.htm Edgar Link pending
orgo-ex32_1.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
orgo-20230331_def.xml Edgar Link unprocessable
orgo-20230331_cal.xml Edgar Link unprocessable
orgo-20230331_lab.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
orgo-20230331_pre.xml Edgar Link unprocessable
orgo-20230331_htm.xml Edgar Link completed
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending